About the Event

The government is stepping up its efforts to boost the capability and capacity of the nation's bio-chem defense and pandemic vaccines and therapeutics industry. To support this goal, additional funding and incentives are being pushed on several fronts. Congress appropriated over $3.8 billion for Fiscal Year 2006 for pandemic influenza preparedness, including the purchase of vaccines and therapeutics, and targeted efforts to help accelerate the research and development of advanced technologies and medical countermeasures. Senator Burr's “Biodefense and Pandemic Vaccine and Drug Development Act” includes rebates and grants to incentivize manufacturers to build vaccines and therapeutics production facilities in the U.S., as well as the creation of an advanced development office to bridge the "valley of death" for emerging technologies. Still, over $3 billion of Project Bioshield's appropriation has yet to be earmarked for specific procurements.

The government's bio-chem defense and pandemics program—designed to rapidly develop biodefense and pandemic vaccines and therapeutics, accelerate their testing and approval, expand their production, and place them into the nation's stockpile—is predicated on strong collaboration between industry, academia and government in achieving its success.

The 4th Bio-chem Defense & Pandemic Vaccines and Therapeutics will again provide detailed information about the role universities, pharmaceutical companies and the biotechnology industry can play in addressing the Nation's need for bio-chem defense and pandemic vaccines and therapeutics. The Government's top bio-chem defense and pandemic leaders will be on hand to help you identify the opportunities for your participation and provide the crucial information you'll need to make informed decisions about your involvement. Senior representatives from pharmaceutical companies will provide their perspectives on what is needed to build a profitable and viable bio-chem defense and pandemic vaccine and therapeutic business sector.

Pre-Conference Symposium

Late Stage Biodefense Vaccines and Therapeutics Developments Chaired by: Michael Kurilla, M.D., Director, Office of BioDefense Research Affairs, NIAID, NIH George Ludwig, Ph.D., Science Director, USAMRIID Monday, April 24, 2006 This pre-conference Symposium will provide a briefing by leading biodefense researchers on late stage biodefense vaccines and therapeutics developments and the unique challenges facing them.

THE NETWORKING FAIR Explore partnership and collaboration opportunities In what has traditionally developed into a key part of the event, the Networking Fair provides the ideal opportunity for representatives from government, pharmaceutical and biotechnology companies, and universities to come together to explore opportunities for partnering and collaboration. Past attendees have found the Fair a great value-add to their conference experience. The Fair will feature: Government "help desks" where conference attendees can ask government representatives questions about current opportunities to collaborate with the government on the development and production of vaccines and therapeutics Companies and universities sharing information and showcasing their capabilities

Click Here to Download Brochure.